Idorsia Investments

Idorsia is a Swiss biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative small molecule therapeutics. Spun off from Actelion in 2017 following its acquisition by Johnson & Johnson, Idorsia has rapidly established a diverse clinical pipeline targeting various therapeutic areas including CNS, cardiovascular, and rare diseases. The company has successfully brought multiple products to market, including Quviviq for insomnia and Tryvio for resistant hypertension. Headquartered in Allschwil, Switzerland, Idorsia leverages its deep expertise in medicinal chemistry to address significant unmet medical needs. Despite recent financial restructuring, the company maintains a strong focus on late-stage clinical development and global commercial expansion.